Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial

Per Olov Hedlund, Robert Johansson, Jan Erik Damber, Inger Hagerman, Peter Henriksson, Peter Iversen, Ole Peter Klarskov, Peter Mogensen, Finn Rasmussen, Eberhard Varenhorst, SPCG-5 STUDY GROUP

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    15 Citationer (Scopus)

    Abstract

    This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.
    OriginalsprogEngelsk
    TidsskriftScandinavian Journal of Urology and Nephrology
    Vol/bind45
    Udgave nummer5
    Sider (fra-til)346-53
    Antal sider8
    ISSN0036-5599
    DOI
    StatusUdgivet - 2011

    Citationsformater